Home » AGEB Journal » Issues » Volume 78" » Fasc.4 - Case series » Article details

Endoluminal Bariatric Interventions : Where do we stand ? Where are we going ?

Journal Volume 78 - 2015
Issue Fasc.4 - Case series
Author(s) Ozan Unlu, Alexis Okoh, Bulent Yilmaz, Emir C. Roach, May Olayan, Abdullah Shatnawei
Full article
Full Article
VIEW FREE PDF
(1) Department of Gastroenterology, Hacettepe Faculty of Medicine, Ankara, Turkey ; (3) Department of Gastroenterology, Selcuk University Faculty of Medicine, Konya, Turkey ; (2) Endocrine and Metabolism Institute, (4) Department of Pathobiology, (5) Department of Internal Medicine, (6) Department of Gastroenterology, Cleveland Clinic, Cleveland, OhiO. USA.

Background : Obesity is an epidemic leading to high morbidity, mortality, and therefore health-related costs. Thus, there is a huge need for development of safe and effective treatments. Even though success rates of conservative methods are highly limited, the surgi- cal approaches lead to major complications in as many as 25% of the patients. In this study, we aimed to review the currently avail- able, less-invasive, endoscopic bariatric techniques which provides an option to reduce the risks of the patients and the medical costs. Methods : A systematic literature review through Pubmed and Medline was performed to find the studies on this topic, and all controlled clinical trials, case reports, and case series were re- viewed. Results : Endoluminal bariatric interventions include restrictive, malabsorptive approaches, and other techniques including trans- pyloric shuttle, botulinum toxin, gastric pacing and vagal nerve stimulation. Restrictive procedures act by limiting the gastric vol- ume and leading to early satiety, while malabsorptive procedures create a malabsorption state. Transpyloric shuttle is a device de- creasing the rate of gastric emptying. Botox injection causes a delay in gastric emptying, and vagal nerve stimulation modulates eating behavior. Conclusion : Endoluminal bariatric techniques can become the primary choice of therapy in the near future for bariatric care. (Acta gastroenterol. belg., 2015, 78, 415-423).

© Acta Gastro-Enterologica Belgica.
PMID 26712053